Touil Yasmine, Igoudjil Wassila, Corvaisier Matthieu, Dessein Anne-Frédérique, Vandomme Jérôme, Monté Didier, Stechly Laurence, Skrypek Nicolas, Langlois Carole, Grard Georges, Millet Guillaume, Leteurtre Emmanuelle, Dumont Patrick, Truant Stéphanie, Pruvot François-René, Hebbar Mohamed, Fan Fan, Ellis Lee M, Formstecher Pierre, Van Seuningen Isabelle, Gespach Christian, Polakowska Renata, Huet Guillemette
Authors' Affiliations: INSERM U837 Team 4 "Molecular and Cellular Targeting of Cancers"; SIRIC ONCOLille; INSERM U837 Team 5 "Mucins, Epithelial Differentiation, and Carcinogenesis" Jean-Pierre Aubert Research Centre, Université Lille and CHU, Univ Nord de France; Unit of Biostatistics; Department of Digestive Surgery and Transplantation; Department of Medical Oncology, CHU, Univ Nord de France; IBL UMR-8161 CNRS, Université Lille Nord de France, Institut Pasteur, Lille; IRI USR 3078 CNRS, Villeneuve d'Ascq; INSERM U938, Molecular and Clinical Oncology, Hôpital Saint Antoine, Université Pierre et Marie Curie 6, Paris, France; and The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res. 2014 Feb 15;20(4):837-46. doi: 10.1158/1078-0432.CCR-13-1854. Epub 2013 Dec 9.
Metastasis and drug resistance are the major limitations in the survival and management of patients with cancer. This study aimed to identify the mechanisms underlying HT29 colon cancer cell chemoresistance acquired after sequential exposure to 5-fluorouracil (5FU), a classical anticancer drug for treatment of epithelial solid tumors. We examined its clinical relevance in a cohort of patients with colon cancer with liver metastases after 5FU-based neoadjuvant chemotherapy and surgery.
We show that a clonal 5F31 cell population, resistant to 1 μmol/L 5FU, express a typical cancer stem cell-like phenotype and enter into a reversible quiescent G0 state upon reexposure to higher 5FU concentrations. These quiescent cells overexpressed the tyrosine kinase c-Yes that became activated and membrane-associated upon 5FU exposure. This enhanced signaling pathway induced the dissociation of the Yes/YAP (Yes-associated protein) molecular complex and depleted nuclear YAP levels. Consistently, YES1 silencing decreased nuclear YAP accumulation and induced cellular quiescence in 5F31 cells cultured in 5FU-free medium. Importantly, YES1 and YAP transcript levels were higher in liver metastases of patients with colon cancer after 5FU-based neoadjuvant chemotherapy. Moreover, the YES1 and YAP transcript levels positively correlated with colon cancer relapse and shorter patient survival (P < 0.05 and P < 0.025, respectively).
We identified c-Yes and YAP as potential molecular targets to eradicate quiescent cancer cells and dormant micrometastases during 5FU chemotherapy and resistance and as predictive survival markers for colon cancer.
转移和耐药性是癌症患者生存及治疗中的主要限制因素。本研究旨在确定HT29结肠癌细胞在先后暴露于5-氟尿嘧啶(5FU,一种治疗上皮实体瘤的经典抗癌药物)后获得化疗耐药性的潜在机制。我们在一组接受基于5FU的新辅助化疗和手术治疗后发生肝转移的结肠癌患者中研究了其临床相关性。
我们发现,对1 μmol/L 5FU耐药的克隆性5F31细胞群体表现出典型的癌症干细胞样表型,再次暴露于更高浓度的5FU时进入可逆的静止G0期。这些静止细胞过度表达酪氨酸激酶c-Yes,在5FU暴露时被激活并与膜相关。这种增强的信号通路诱导Yes/YAP(Yes相关蛋白)分子复合物解离并降低核YAP水平。一致地,在无5FU培养基中培养的5F31细胞中,YES1沉默减少了核YAP积累并诱导细胞静止。重要的是,在接受基于5FU的新辅助化疗的结肠癌患者的肝转移灶中,YES1和YAP转录水平更高。此外,YES1和YAP转录水平与结肠癌复发及患者较短生存期呈正相关(分别为P < 0.05和P < 0.025)。
我们确定c-Yes和YAP是在5FU化疗及耐药过程中根除静止癌细胞和休眠微转移灶的潜在分子靶点,也是结肠癌的预测生存标志物。